AstraZeneca provides update on phase III trial of selumetinib in non-small cell lung cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
Ämnen: Forskning
-
-
AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2016
De totala intäkterna minskade som förväntat med 3%, vilket återspeglar en minskning i produktförsäljning med 2% och är drivet av patentutgångar, i synnerhet Crestor i USA. Merparten av intäkterna från externa samarbeten förväntas ligga under andra halvåret.
-
AstraZeneca’s antibiotic Zavicefta met primary endpoints in phase III trial for treatment of hospital-acquired pneumonia
AstraZeneca today announced positive results from the Phase III REPROVE trial for Zavicefta (ceftazidime-avibactam), a new combination antibiotic for the treatment of a broad range of serious Gram-negative bacterial infections in hospitalised patients.
-
ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES
AstraZeneca today announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
-
Tagrisso met primary endpoint in Phase III 2nd-line lung cancer trial
Tagrisso demonstrated superior progression-free survival compared to standard platinum-based chemotherapy,with a safety profile consistent with previous trials First randomised trial to evaluate the clinical benefit of an EGFR T790M medicine, and data are consistent with those supporting Tagrisso approvals
-
Inbjudan till AstraZeneca och Läkartidningens seminarium i Almedalen om jämlik cancervård 4 juli 14.10-15.00
Hur får vi en jämlik cancerbehandling i Sverige och hur kan ”ordnat införande” bidra? Vilka utmaningar och möjligheter finns för introduktion av nya cancerbehandlingar idag? Hur har processen med nationellt ordnat införande förändrat vår förmåga att jämlikt kunna erbjuda nya behandlingar, över hela landet? Vilka är lärdomarna? Hur ser uppföljningen ut? Hur vill vi ha det om 5 år?
-
AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy areas
AstraZeneca also licenses European rights to LEO Pharma for brodalumab, a potential new medicine for psoriasis
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation -
New antibiotic ZAVICEFTA approved in the European Union for patients with serious bacterial infections
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
-
AstraZeneca provides update on FluMist Quadrivalent vaccine in the US for the 2016-17 influenza season
AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent Live Attenuated Influenza Vaccine (FluMist Quadrivalent) in the US for the 2016-2017 influenza season.
-
Christer Betsholtz appointed new Head of Karolinska Institutet and AstraZeneca’s Integrated Cardio Metabolic Centre
Karolinska Institutet and AstraZeneca have today announced the appointment of Professor Christer Betsholtz as the new Director of their Integrated Cardio Metabolic Centre (ICMC) in Stockholm, Sweden.
Christer Betsholtz,PhD, is a leading scientific authority in the field of vascular biology with more than 300 publications. He is currently professor with tenure at Uppsala University and Karolinsk -
AstraZeneca ingår kommersialiseringsavtal med Aspen för produktportföljen inom anestetika
Avtalet utökar den kommersiella räckvidden för anestetika och stödjer bolagets tydliga fokus på innovativa, nya läkemedel inom tre huvudterapiområden
-
LYNPARZA (OLAPARIB): LATEST DATA SUGGEST POTENTIAL OVERALL SURVIVAL ADVANTAGE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER
AstraZeneca presented (at ASCO in the evening of June 5) results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial.
-
TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER
Osimertinib data reported at ASCO 2016 demonstrated improved neurological function in patients with EGFRm NSCLC and leptomeningeal disease Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
-
AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America
Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout
-
Positive CHMP opinion in EU for saxa/dapa (saxagliptin and dapagliflozin) for adults with type-2 diabetes
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. .
-
AstraZeneca’s Faslodex met primary endpoint in first-line treatment of advanced breast cancer
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer
-
AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalaemia
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca
-
STUDIE VISAR ATT ”MOBIL-APP” FÖRBÄTTRADE FÖLJSAMHET TILL BEHANDLING EFTER HJÄRTINFARKT
Resultaten från den svenska SUPPORT-studien, som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt med hjälp av en mobiltelefonapplikation, publiceras nu i American Heart Journal. Studien visar att de patienter som fick ett interaktivt patientverktyg i form av en ”mobil-app” i högre grad tog sitt blodproppshämmande läkemedel ticagrelor enligt läkarens ordination.
-
AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016 - Leadership in DNA damage response therapies
73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour types Continued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation, and new data in first-line NSCLC
-
AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer
AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein.
Visa mer
Loading...